Stephen R. Wedge

Newcastle Upon Tyne, ENG NE17RU, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.

Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.

Journal: Journal of medicinal chemistry

Published: December 23, 2025

Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release.

Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release.

Journal: Journal of medicinal chemistry

Published: August 30, 2023

Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy.

Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy.

Journal: Journal of medicinal chemistry

Published: April 01, 2023

Fragment expansion with NUDELs - poised DNA-encoded libraries.

Fragment expansion with NUDELs - poised DNA-encoded libraries.

Journal: Chemical science

Published: March 03, 2023

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 20, 2022

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor.

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor.

Journal: Journal of medicinal chemistry

Published: April 25, 2022

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.

Journal: Journal of medicinal chemistry

Published: July 02, 2021

Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma.

Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma.

Journal: British journal of cancer

Published: May 29, 2021

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.

Journal: Journal of medicinal chemistry

Published: March 24, 2021

DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models.

DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models.

Journal: Molecular cancer therapeutics

Published: October 06, 2020

Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.

Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.

Journal: European journal of medicinal chemistry

Published: February 25, 2019

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.

Journal: The Journal of clinical investigation

Published: January 15, 2019

Showing 1-12 of 35

Last Updated: 09/26/2026